The highest profile medtech news out of this year's European Society of Cardiology Congress was the presentation of the MITRA-FR results, which cast doubt on the benefits of treating severe secondary mitral valve regurgitation with Abbott Vascular's MitraClip. (Also see "ESC Congress 2018: MITRA-FR Finds No Benefit Of MitraClip In Severe Secondary MR" - Medtech Insight, 31 August, 2018.) But the Munich meeting also featured several other noteworthy device-trial presentations. Here's a look at a few of them.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?